In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh welcomes Dr Carl Marci, chief psychiatrist and managing director of mental health and neuroscience at OM1 to discuss
A proposed order by the Federal Trade Commission (FTC) would impose a $7 million fine on telehealth company Cerebral in connection with charges that it disclosed its custo
Shares in Intra-Cellular Therapies rose sharply after it reported that its only product Caplyta was effective for a new indication, major depressive disorder (MDD), in a p
Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that
Three digital health technologies (DHTs) used to support patients with psychosis can be used by the NHS while additional evidence of their benefits is gathered.
Novartis has posted a healthy rise in sales and profits in the first full quarter since it separated from Sandoz and proposed former Bristol Myers Squibb’s chief executive
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.